

Medicines Update: November 2025

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Table 1 shows the new marketing authorisations for November 2025

TABLE 1: New marketing authorisations in November 2025

New Marketing Authorisations			
Product name and target species	Active substance	Authorisation Holder, territory, and distribution category	Therapeutic group
Food Animals			
Lyncoo 400 mg/g Powder for Use in Drinking Water for Pigs and Chickens	Lincomycin	Endectovet EOOD GB & NI, POM-V	Antimicrobial
Non-food Animals			
None			

See the VMD's [Product Information Database \(www.gov.uk/check-animal-medicine-licensed\)](http://www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at www.gov.uk/check-animal-medicine-licensed.

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Food producing animals

None

Companion animals

Beaphar WORMclear PLUS Spot-on Solution for Cats [Range]

Novospot Worming Solution Spot-on Solution for Cats [Range]

Pet Shield Worm Screen Spot-on Solution for Cats [Range]

Praziquantel/Emodepside Krka Worming Spot-on Solution for Cats [Range]

All KRKA, d.d., Novo mesto GB & NI NFA-VPS

The distribution categories for the above products have changed from POM-V to NFA-VPS with the following associated SPC changes:

Section 3.2: The indication for the treatment of lungworm infections has been removed.

Section 3.8: Wording has been added recommending that veterinary advice should be sought before treatment if a cat is receiving other medications, and to inform the vet that this product is being used if other medication is provided.

Section 3.9: Additional text has been included stating that the need for, and frequency of, re-treatments should be based on professional advice and should take into account individual risk factors (the local epidemiological situation and the animal's lifestyle).

CaniTrio Chewable Tablets for Dogs [Range]

Zoetis UK Limited GB POM-V

Section 3.2: Addition of two new indications:

- The treatment of *Angiostrongylus vasorum*, along with associated dosing information and precautions.
- Reduction in the risk of *Dipylidium caninum* via transmission by *Ctenocephalides felis*.

Cazitel Plus Tablets for Dogs

Chanelle Pharmaceuticals Manufacturing Ltd NI NFA-VPS

Section 3.6 of the SPC: Updated to include of adverse events: lethargy, anorexia, and hyperactivity at a frequency of very rare (<1 animal/10,000 animals treated, including isolated reports).

Prazitel Plus XL Tablets for Dogs

Chanelle Pharmaceuticals Manufacturing Ltd NI NFA-VPS

Section 3.6 of the SPC: Updated to include adverse events lethargy, anorexia and hyperactivity at a frequency of very rare (<1 animal/ 10,000 animals treated, including isolated reports).

YURVAC RHD Emulsion for Injection for Rabbits

Laboratorios Hipra SA GB & NI POM-V

Section 3.6 of the SPC: Updated to include adverse events anorexia and intestinal stasis at a frequency of very rare (<1 animal/ 10,000 animals treated, including isolated reports).

For more information, contact the VMD at postmaster@vmd.gov.uk